Light-Chain and Transthyretin Cardiac Amyloidosis in Severe Aortic Stenosis: Prevalence, Screening Possibilities, and Outcome

Figure 1. Patient population: 238 patients scheduled for transcatheter aortic valve replacement (TAVR) were screened. Reasons for exclusion and screening modalities are displayed. AS, aortic stenosis; CA, cardiac amyloidosis; CMR, cardiac magnetic resonance; 99mTc‐DPD, 99mTc‐labelled 3,3‐diphosphono‐1,2‐propanodicarboxylic‐acid scintigraphy; echo, transthoracic echocardiography.

Figure 2. Stroke volume index (SVi) and voltage/mass ratio (VMR) for the discrimination of aortic stenosis with/without cardiac amyloidosis. SVi as well as VMR showed good discriminative power for the distinction of aortic stenosis with/without cardiac amyloidosis. AUC, area under the curve; MCF, myocardial contraction fraction; MR‐ECV, extracellular volume by cardiac magnetic resonance.

Figure 3. Kaplan–Meier curves of patients with aortic stenosis (AS) with/without cardiac amyloidosis (CA). Concomitant cardiac amyloidosis (CA‐AS) was not associated with all‐cause mortality (A) or cardiovascular (CV) hospitalization (B) over 15.3 ± 7.9 months following transcatheter aortic valve replacement. One CA‐AS patient died prior to transcatheter aortic valve replacement and was therefore excluded from outcome analysis.